Navigation Links
Promising therapy for relapsing multibple sclerosis
Date:2/16/2010

SALT LAKE CITY An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.

Multiple sclerosis (MS) is a debilitating disease in which the body's immune system attacks the fatty substance that surrounds and protects the nerve fibers in the brain and spinal cord. The resulting damage interferes with the transmission of nerve signals between the brain and spinal cord and other parts of the body, producing a variety of symptoms including problems with balance, coordination, vision, and even mental function. Approximately 85 percent of multiple sclerosis patients are initially diagnosed with relapsing MS, in which clearly-defined attacks of worsening neurologic function are followed by partial or complete recovery periods during which no disease progression occurs.

"Previous research has shown that treatment with daclizumab reduced multiple sclerosis disease activity," says John W. Rose, M.D., professor of neurology at the University of Utah School of Medicine, Neurovirology Research Laboratory, Veterans Affairs Salt Lake City Health Care System and the University of Utah, an author on the study. "Our work in the CHOICE trial shows that daclizumab significantly reduces MS lesion formation in people with active relapsing disease."

Monoclonal antibodies are immune system proteins that preferentially bind to specific target cells, triggering the immune system to attack those cells. Daclizumab is a monoclonal antibody specific for CD25, a protein that is expressed on activated T cells, and binding of daclizumab to CD25 results in selective inhibition of these activated T cells. Daclizumab treatment has been studied in patients with human autoimmune conditions, such as
'/>"/>

Contact: Dennis Jolley
dennis.jolley@hsc.utah.edu
801-581-5777
University of Utah Health Sciences
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. First blinded study of venous insufficiency prevalence in MS shows promising results
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Promising new neuroimaging techniques for early detection of Alzheimers disease
4. LSUHSC research yields promising stroke treatment
5. Promising New Results On The Added Safety Of Using SmokeStik Electronic Cigarettes In The Bid To Quit Smoking
6. UV LED therapy shows promising results in preventing focal seizures
7. New insights into mushroom-derived drug promising for cancer treatment
8. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
9. Promising pharmaceutical agents emerge as sports doping products
10. Pneumonia Drug Promising Against Form of Muscular Dystrophy
11. Health Alliance Announces Promising Nine-Month Results from First Ever Outcome-Based Reimbursement Program for Actonel(R) (risedronate sodium) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... Alexandria, VA (PRWEB) July 31, 2014 ... Hilton hotel in Chicago, Illinois, the Mesothelioma Applied ... Chicago Medicine, will host a one-day regional ... members, covering a variety of topics related to ... , Some of the covered topics will include ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Leelanau Peninsula’s newest ... July 3, 2014 at 7788 East Horn Road in Lake ... Wine Trail , Aurora Cellars is the 25th winery along ... including the popular wine tour events, making its trail event ... 6-7, 2014. , Owners David and Faye Mathia opened ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary will ... on Monday, September 15, with its 2014 Opening Convocation, ... 3440 Shroyer Rd., Kettering, OH. Dr. Emma J. Justes, ... Emma Toussant Chair will speak on “Unexpected Undercurrents: Responding ... teaching and research interests include pastoral care and counseling, ...
(Date:7/31/2014)... Memphis, TN (PRWEB) July 31, 2014 In ... are required for proper storage of necessary life saving ... and staff. Unfortunately there is still a high number of ... is an EMT who steals the narcotics and even replaces ... urgent relief receives none. As seen in the case in ...
Breaking Medicine News(10 mins):Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:United Theological Seminary to Open 144th Year 2Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2
... inheritable genes to enable people to produce more ‘perfect’ ... and on being human, warns a leading US science ... out great hope for IGM technology, which offers them ... Disease and schizophrenia on to their children.// ,However, ...
... the risk of pancreatic cancer in both sexes,while moderate ... obese individuals,says Dr. Dominique S. Michaud the head ... National Cancer Institute in Rockville, Maryland and colleagues collected ... 75 years of age, who participated in the Health ...
... popular belief, the heart can actually repair itself by growing new ... researchers in New York and Italy. Dr. Piero Anversa and colleagues ... heart muscle cells called myocytes continued to divide after a heart ... examined the hearts of 13 people who died within a few ...
... patients suffering from Angina may have some new treatment ... Angina, a common cardiovascular disorder affecting millions of people ... by blood vessels too clogged to get oxygen-rich blood ... either medication or for more serious cases, rerouting the ...
... piglets last week could significantly increase the success rate ... research has indicated that rejection of animal cells and ... to the presence of the gene alpha 1,3 galactosyl ... a sugar// to the surface of pig cells, flagging ...
... A new technique to keeping heart arteries flowing easily ... solving a major weakness of the common procedure.Doctors ... - the drug-coated stent. In testing on 30 patients ... percent effective, an accomplishment almost unheard of in medicine.// ...
Cached Medicine News:Health News:Perfect babies boon or a bane? 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3Health News:Xenotransplantation “breakthrough” 2Health News:A ray of hope in Angioplasty dilemma 2
(Date:7/31/2014)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at June 30, ... March 31, 2014."The second half of 2014 will be an ... milestones for a number of our late-stage clinical programs," said ... "The first of these is the potential US and EU ...
(Date:7/31/2014)...  UBM Medica US announces that Cancer ... presents exclusive slide shows dealing with communication in the ... care. Cancer Network, the online ... blogs, and podcasts about the latest clinical findings. Among ... , End-of-life care is challenging for even the ...
(Date:7/31/2014)... July 31, 2014  Decision Resources Group is launching ... product Marketrack to now include ChinaTrack; the new capabilities ... in an interactive dashboard providing detailed brand-level share tracking ... a hospital level. Other key capabilities of ... feed: In addition to end-user surveys of healthcare facilities, ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Swiss Exchange: CRX) today announced that following the end of ... Johnson & Johnson has acquired 98.89% of the issued Shares ... Crucell) and 98.93% of the issued and outstanding Shares in ...
... Cellceutix Corporation (Pink Sheets: CTIX ) today ... Agreement (CDA) pertaining to its anti-cancer drug, Kevetrin™, with ... Cellceutix CEO, Leo Ehrlich, commented, "It,s relatively uncommon ... a compound before clinical trials are underway.  The process ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3
... WH, the latest in the Magnes line of ... and its full cortical coverage, provides the highest ... allowing study of a wide range of neuronal ... choice of detector configurations and can be equipped ...
... a non-invasive and painless method of stimulating ... Laboratories manufactures two magnetic stimulation devices, the ... (HSMS). The Hight Speed MES-10 ... up to 25 Hz at full power. ...
... MOBEE headboxes are the ... line of portable battery-powered ... a robust new mechanical ... software, XLTEK's standard MOBEE24plus ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: